Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. / Deacon, Carolyn F.

In: Current Opinion in Investigational Drugs, Vol. 9, No. 4, 2008, p. 402-13.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Deacon, CF 2008, 'Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.', Current Opinion in Investigational Drugs, vol. 9, no. 4, pp. 402-13.

APA

Deacon, C. F. (2008). Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Current Opinion in Investigational Drugs, 9(4), 402-13.

Vancouver

Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Current Opinion in Investigational Drugs. 2008;9(4):402-13.

Author

Deacon, Carolyn F. / Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. In: Current Opinion in Investigational Drugs. 2008 ; Vol. 9, No. 4. pp. 402-13.

Bibtex

@article{b274d8a0ab4811ddb5e9000ea68e967b,
title = "Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.",
abstract = "Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.",
author = "Deacon, {Carolyn F}",
note = "Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Humans; Hypoglycemic Agents; Molecular Structure; Patents as Topic; Piperidines; Structure-Activity Relationship; Treatment Outcome; Uracil",
year = "2008",
language = "English",
volume = "9",
pages = "402--13",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

AU - Deacon, Carolyn F

N1 - Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Humans; Hypoglycemic Agents; Molecular Structure; Patents as Topic; Piperidines; Structure-Activity Relationship; Treatment Outcome; Uracil

PY - 2008

Y1 - 2008

N2 - Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.

AB - Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.

M3 - Journal article

C2 - 18393107

VL - 9

SP - 402

EP - 413

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 4

ER -

ID: 8416764